Synergizing Science and Software in Precision Formulation of Membrane-Adhesive Tablets

Research Article

Synergizing Science and Software in Precision Formulation of Membrane-Adhesive Tablets

  • Kratika Khadsondni
  • Kratika Khadsondni
  • Tushar Sonare
  • Aman Kumar
  • Akash Yadav
  • Dinesh Kumar Jain

IPS Academy College of Pharmacy, Indore, Madhya Pradesh, India.

*Corresponding Author: Akash Yadav, IPS Academy College of Pharmacy, Indore, Madhya Pradesh, India.

Citation: Khadsondni K., Mandloi K., Sonare T., Kumar A., Yadav A., et al. (2025). Synergizing Science and Software in Precision Formulation of Membrane-Adhesive Tablets, Journal of Clinical Research and Clinical Trials, BioRes Scientia Publishers. 4(4):1-17. DOI: 10.59657/2837-7184.brs.25.054

Copyright: © 2025 Akash Yadav, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: March 11, 2025 | Accepted: August 20, 2025 | Published: August 30, 2025

Abstract

Introduction: Hypertension affects over a billion people worldwide, necessitating efficient and patient-friendly treatment solutions. Propranolol hydrochloride, a commonly used beta-blocker, requires an optimized drug delivery system to enhance therapeutic efficacy and patient compliance. This study aims to formulate a novel mucoadhesive bilayer tablet (MBT) of propranolol hydrochloride, integrating an instant-release layer for rapid action and a mucoadhesive extended-release layer for sustained drug delivery.

Methods: A direct compression method was used to formulate the bilayer tablets. Pre- and post-compression evaluations ensured compliance with quality standards. Optimization was conducted using the Box-Behnken design, a response surface methodology, to determine the ideal formulation parameters for drug release.

Results: The optimized batch, MBT 16, demonstrated desirable immediate and sustained drug release profiles. The formulation exhibited effective pharmacokinetic properties, ensuring steady blood pressure control throughout the day. Additionally, the use of natural excipients enhanced safety and affordability.

Conclusion: The developed mucoadhesive bilayer tablet improves propranolol hydrochloride’s therapeutic profile by reducing dosing frequency while maintaining consistent blood pressure regulation. This innovation enhances patient adherence and opens new possibilities for advanced hypertension management through novel drug delivery systems.


Keywords: mucoadhesive bilayer tablet; propranolol hydrochloride; Box-Behnken design; sustained release; hypertension management

Introduction

Hypertension, often known as high blood pressure, affects over one billion people globally and is a leading cause of cardiovascular disease and mortality. It remains the primary cause of death worldwide. Globally, cardiovascular diseases claimed 17.9 million lives in 2019. Premature deaths in India from heart disease rose from 23.02 million in 1990 to 37 million in 2010, representing a 59% increase in years of life lost. Hypertension is a chronic illness characterised by consistently elevated blood vessel pressure. Often exhibiting no symptoms, high blood pressure is referred to as “the silent killer” [1-3].

A unique method for delivering medications with increased benefits is the use of specialised tablets. Enhancing the bioavailability of the active ingredient via either targeting organ or tissue locations or utilising innovative drug-delivery methods that initiate certain processes is the fundamental idea behind the tailored tablet. Specialised tablets fall into one of two categories: modified-release tablets, which are characterised by their drug-release pattern, or organ-specific tablets, which are characterised by their drug targeting to an organ. Bilayer tablets are a type of dosage in which one or two different types of medicine are mixed together in different levels of compression. A variety of pharmacological and dosage form deficiencies are addressed by the dose type. A bilayer pill frequently contains both an initial and a maintenance dosage [4-6].

Figure 1: Bilayer tablet.

A nonselective beta-blocker, propranolol hydrochloride (Propranolol HCl) is frequently used to treat a variety of cardiovascular and other disorders. It lowers blood pressure by decreasing the heart's contraction force and tempo. Propranolol is a lipophilic (fat-soluble) medication that can enter the circulation by evading the gastrointestinal tract's lipid bilayer of cell membranes. It is not as well absorbed as other water-soluble drugs, and first-pass metabolism affects its bioavailability. The liver's significant first-pass digestion reduces its bioavailability to 25–35%. Absorption is affected by stomach pH, lipophilicity of the medication, and food intake. In response to norepinephrine and epinephrine, the heart's beta-1 receptors speed up the heartbeat. Propranolol inhibits these receptors, which lowers heart rate (negative chronotropic effect). It can be found in large quantities in the brain, adipose tissues, kidneys, lungs, and heart [7-9].

The main purpose of this study was to develop a new drug delivery system for the efficient treatment of hypertension, a chronic heart condition. Propranolol hydrochloride, a beta-blocker frequently used to treat hypertension, is the focus of this study's bilayer tablet formulation and design. The proposed tablet design consisted of two distinct layers: an immediate release layer and a mucoadhesive extended-release layer. We used the direct compression method to build both layers. For the first dose of the drug to have therapeutic benefits, an instant release layer was designed to deliver it quickly. Simultaneous adhesion of the mucoadhesive extended-release layer to the gastrointestinal mucosa allows for longer-lasting medication release. This dual-layer approach aims to optimize the pharmacokinetic profile of propranolol hydrochloride, which may enhance patient compliance by reducing dose frequency while maintaining constant blood pressure control throughout the day. The positive aspects of employing direct compression as the manufacturing process simplicity, affordability, and scalability make large-scale production of these bilayer tablets desirable [10-11].

The Box-Behnken design is an independent quadratic design that does not contain an embedded factorial or fractional factorial design. In this design, the treatment combinations were at the midpoints of the edges of the process space and at the centre. The research study involves the use of Box Behnken Optimization software leveraging natural Disintegrant Potato starch, natural Mucoadhesive polymer Chia seed mucilage. The incorporation of natural ingredients is an eco-friendly and biocompatible alternative to other synthetic agents of the same category, although the agents have their own synergistic effect. The research insight to boost the efficacy and therapeutic effectiveness of the selected active ingredient [12-14].

Materials and Methods

Propranolol Hydrochloride was obtained as a gift sample from Algen healthcare limited, HPMC K4M and HMPM K15 were purchased from LOBA Chemie. Other excipients used to prepare the bilayer tablets were of standard quality and all chemical reagents used were of analytical grade.

Table 1: Physical and chemical parameters of Propranolol HCl.

S. No.ParameterPredicted Value
1Molecular FormulaC16H21NO2
2Molecular Structure
3IUPAC Name1-(naphthalen-1-yloxy)-3-[(propan-2 yl)amino]propan-2-ol
4Molecular Weight295.85 gm/mol
5BCS ClassClass I
6pH and pKa5-6 pH and 14.09
7Log P3.03 or 2.58
8Crystallinitywhite, crystalline solid
9Melting Point96°C
10SolubilityHighly soluble in water

Extraction of Chia Seed Mucilage

The extraction of chia seed mucilage was done according to the methodology adapted by Silveira Ramos et.al. (2021). The seeds were soaked in the Distilled water at a ratio of 1:30 for about 3 hours. After which the mixture was continuously stirred by using magnetic stirred at a temperature of 70-80 ◦C for approximately 1 hour. After extraction the mixture was filtered using a muslin cloth. The extracted material was precipitated with the absolute ethanol. The precipitated mucilage was the subjected towards the hot air oven for drying at temperature 40◦C for about 24 hours [15-16].

Figure 2: Extraction of chia seed mucilage.

Extraction of Potato Starch

Raw potato was selected, washed and peeled and was cut into small pieces. Blending or crushing was done to form slurry using distilled water. The slurry was then allowed to stand for about 24 hours for sedimentation. Decantation was done to separate the starch and washed with distilled water. Finally, the starch was dried at 40 °C for 48 hours and stored in air tight container [17].

Figure 3: Extraction of potato starch.

Preparation of Aloe Vera Mucilage Powder

Fresh leaves Aloe vera (Aloe barbadensis) was identified and inner leaves mucilage was collected. Excess water was removed and the slake was washed using the acetone. After which the resultant material was soaked in ethyl acetate for precipitation. Resultant material was spread to allow the evaporation of ethyl acetate. Finally dried for about 4 hours and passed to through mesh size 250μm. Store in air tight container [18].

Figure 4: Extraction of Aloe vera mucilage powder.

Table 2: Evaluation parameters of extracted material.

S. No.EvaluationResult
Chia Seed MucilageAloe Vera Mucilage PowderPotato Starch
1ColourLight brownLight beigeWhite
2OdourSlightly earthySlightly herbaceousOdourless
3TasteNeutral tasteSlightly bitterTasteless
4AppearanceFine and clumpyFine powderyFine powder
5NatureHydrophilicHydrophilicHydrophilic
6Melting point-38 °C-
7pH6-75-76-7
8Swelling Index10ml/g6.8ml/g7.5 ml/g

Box-Behnken Design (BBD)

The three levels of a factor 1 being the higher level, 0 being the intermediate level, and -1 being the lower level should be investigated in the box-Behnken design response surface technique. Three independent and three dependent variables were arranged in a polynomial model using BBD and design expert software. The three independent variables, X1, X2, and X3, are the concentration of the disintegrant (potato starch), the impact of the sustain release polymer, and the influence of the mucoadhesive polymer (chia seed mucilage), as indicated in the table 3.

Table 3: The table showing the independent variable and the levels that are selected.

S. No.Independent Variablelevels
-1(lower level)+1(higher level)
1Concentration of disintegrant (potato starch)1220
2effect of mucoadhesive polymer (chia seed mucilage)1825
3effect of sustain release polymer1620

The impact of these three independent variables' changes on the three dependent variables (Y1, Y2, and Y3) are disintegration time, mucoadhesive strength and in-vitro drug release can be studies in the above table 4.

Table 4: Selected Dependent variables.

S. No.Dependent VariablesUnits
1Disintegration TimeSeconds
2Mucoadhesive StrengthGrams
3In-vitro Drug Releasemg/ml

On the basis of the selected independent variables and their responses the design expert software suggests 15 formulation batches shown in the table no. 5 by using the suggested data from the software we can formulate the tablets by using suitable compression method.

Table 5: Formulation Runs as per Box Behnken design.

RunsConcentration of Disintegrant (Potato Starch)Effect of Mucoadhesive Polymer (Chia Seed Mucilage)Effect of Sustained Release Polymer
12021.516
21621.518
3162516
4121818
51621.518
6122518
72021.520
8161816
91221.516
10202518
111221.520
12162520
131621.518
14201818
15161820

Preparation of Tablets

The Mucoadhesive bilayer tablets were prepared by using direct compression technique in which the powder blend after lubrication directly compressed using desired compression force and Diameter of die. To prepare a mucoadhesive bilayer tablet, the extended mucoadhesive layer was compressed followed by the compression of burst release layer using Karnavati Tablet punching machine. 

Formulation of Immediate Release Layer

The formulation composition of immediate release layer described in the table no. 6 In these the Potato starch is used as a natural super disintegrating agent to enhance the biocompatibility and biodegradability. Lactose is added as a filler to form a desired dosage unit. All the ingredients were weighed accurately and thoroughly mixed using glass mortar and pestle after that lubricated using magnesium stearate mixed for another 10 minutes. The powder blend was compressed using 11 mm die.

Table 6: Formulation Batches for immediate release layer.

FormulationPropranolol Hcl (mg)Potato starch (mg)Lactose (mg)Magnesium Stearate (mg)
MBT 130201455
MBT 230161495
MBT 330161495
MBT 430121535
MBT 530161495
MBT 630121535
MBT 730201455
MBT 830161495
MBT 930121535
MBT 1030201455
MBT 1130121535
MBT 1230161495
MBT 1330161495
MBT 1430201455
MBT 1530161495

Formulation of Mucoadhesive layer

The formulation composition of mucoadhesive extended-release layer described in the table no. 7 Chia seed mucilage is used as a mucoadhesive polymer and aloevera mucilage is used as a binding agent. While the HPMC K4 M and HPMC K15 is used as a Matrix former to sustain the drug release. Microcrystalline cellulose is used as diluent. All the ingredients were properly mixed thoroughly and lubricated with Talc. Mucoadhesive layer was compressed in 11 mm die followed by compression of immediate release layer [19-23].

Table 7: Formulation batches for mucoadhesive layer.

FormulationPropranolol Hcl (mg)Chia seed mucilage (mg)HPMC K4M (mg)HPMC K15 (mg)MCC (mg)Aloe-Vera (mg)Talc (mg)
MBT 15021.51610137.5105
MBT 25021.51810135.5105
MBT 350251610134105
MBT 450181810139105
MBT 55021.51810135.5105
MBT 650251810132105
MBT 75021.52010133.5105
MBT 850181610141105
MBT 95021.51610137.5105
MBT 1050251810132105
MBT 115021.52010133.5105
MBT 1250252010130105
MBT 135021.51810135.5105
MBT 1450181810139105
MBT 1550182010137105

Pre-compressional Parameter

Pre compressional parameters involve the bulk characterization, powder flow property, solubility, melting point etc. [24-26].

Angle of Repose

It is the angle at which the granular pile can rest on the horizontal surface without fall. The technique measures the resistance between the material particles and critical parameter to measure the flowability and granular packing. Pile forming method was used to identify angle of repose in which a funnel was positioned to hold and release the material slowly onto a smooth flat surface. The height and radius of pile formed by material was notes and the θ was measured using the given equation. 

Formula:

Table 8: Angle of Repose.

S. No.Flow PropertyAngle of Repose
1Excellent25-30
2Good31-35
3Fair36-40
4Passable41-45
5Poor46-55
6Very poor56-65
7Very, very poor>66

Bulk Density

Bulk density is an important physical parameter of powder flow property. It is the density of powder in its natural state and can be calculated by the mass to volume ratio expressed in gm/ml or gm/cm3. It was measured using cylindrical container method in which measuring cylinder was poured with pre-weighed powder material and the volume was directly observed, finally the bulk density was calculated using the formula.

Formula: Bulk density = Mass of substance / Volume of substance

Tapped Density

It is the density of powder after the particular number of mechanically tapping the powder material and calculated by dividing the mass of powder mass by its final volume after tapping. It helps to measure the powder compressibility and flowability expressed in gm/cm3.

Formula: Tapped density = Mass of substance / Final volume after tapping 

Compressibility Index:

Carr’s index measures the powder compressibility which defines the tablet strength and stability. If it is less than 15 indicates the good flowability and if it is more than 25 indicates the poor flowability. 

Formula: Carr’s Index = Tapped Density - Bulk Density / Tapped Density × 100

Table 9: Flow properties as per Carr’s Index.

S. No.Carr’s IndexFlowability
15-15Excellent
212-16Good
318-21Fair possible
423-35Poor
533-38Very poor
6>40Very, very poor

Hausner’s Ratio

It is a critical parameter of powder flow property and measures the flowability or granular material. Low Hausner’s ratio indicates the less interaction between the granular particles and material is more easily flowable. 

Formula: Hausner’ s ratio = Tapped density / Bulk density

Table 10: Flow properties as per Hausner’s Ratio.

S. No.Hausner’ ratioFlowability
11.05 - 1.18Excellent
21.14 - 1.20Good
31.22 - 1.26Fair possible
41.30 – 1.54Poor
51.50 – 1.61Very poor
6>1.67Very, very poor

Particle Size Analysis

Particle size determination of powders is a critical parameter which directly affect the quality, flowability, stability and performance of the substances. Smaller particle size shows higher surface area and have greater absorbance. Sieve method was used to define the particle size of the mixture.

Table 11: Methods for determining particle size of solids.

S. No.TechniquesParticle size (mm)
1Microscopic1-100
2Sieve>5
3Sedimentation>1
4Elutriation1-50
5Centrifugal<50>
6Permeability>1
7Light Scattering0.5-50

Solubility Studies

The amount of material that dissolves in a solution to form a saturated solution at a certain temperature and pressure is known as solubility. The greatest volume or mass of the solute that dissolves in a certain volume or mass of a solvent is how solubility is stated. The shake-flask method was used to determine the solubility:

  • The method involves addition of compound to a medium and shaking it to achieve saturation after giving particular temperature.
  • After formation of supersaturated solution, filtration was done followed by slow cooling and shaking.
  • Sample was then analysed (diluted if needed) to determine the solute content using appropriate method.

Table 12: Characterization of Solubility.

Descriptive TermParts of Solvent Required for 1 Part of SoluteG/L In WaterM=400 Mol/L in WaterM=40000 Mol/L in Water
Very Soluble≤1≥1000≥2,5≥0,025
Freely Soluble1 to 101000 to 1002,5 to 0,250,025 to 0,0025
Soluble10 to 30100 to 330,25 to 0,080,0025 to 0,0008
Sparingly Soluble30 to 10033 to 100,08 to 0,0250,0008 to 0,00025
Slightly Soluble100 to 100010 to 10,025 to 0,00250,00025 to 0,0000025
Very Slightly Soluble1000 to 10,0001 to 0,10,0025 to 0,000250,000025 to 0,0000025
Practically Insoluble, or Insoluble≥10,000≤0,1≤0,00025≤0,0000025

Melting Point Determination

It is the temperature at which the substance starts to melt or changes its state from solid to liquid. It was determined by using electrically heated melting point apparatus.

Loss on Drying

LOD is the resultant weight of the compound expressed in percentage (w/w) to determine the moisture content in the sample compound. Following steps were used to determine the LOD:

  • Sample was accurately weighed.
  • Sample was heated till it gets completely dry.
  • Dried sample was again weighed and difference was calculated.

Standard Calibration Curve

A calibration curve is used to compute the limit of detection, the limit of quantitation, and the concentration of an unknown material. Using a series of standard samples at various concentrations, the instrumental response is used to build the curve. Unknown concentrations can then be predicted by fitting the data with a function.

  • Stock solution of known (1000 μg/ml) concentration was prepared by dissolving 100mg into 100ml of 0.1 N hydrochloric acid.
  • Second stock solution (100 μg/ml) prepared by pipetting 10 ml of above solution and diluted up to 100ml with the same solvent. 
  • Dilutions of different strength was prepared and analysed using UV spectrophotometer.

Post Compressional Parameters

Organoleptic Characters

The organoleptic parameters were studied by visually evaluating tablets properties like colour and odour. 

Thickness

To assess the tablet's homogeneity in size and shape, its thickness was examined.

Methods: A Vernier calliper was used to measure the tablet's thickness.

Hardness

A Monsanto hardness tester was used to measure the tablets' hardness. On the testing platform, each tablet was positioned separately, and pressure was applied until the tablets broke. The hardness value was determined by measuring the force needed to break each tablet. This technique made it possible to assess the tablets' resistance to mechanical stress precisely.

Friability

The Roche Friabilator was used to assess the produced formulations' friability. After a pre-weighed sample of tablets was put in the friability testing and rotated for 100 revolutions, the tablets were cleaned and weighed again. The following formula was used to determine the tablets' friability:

Weight Variation

Twenty tablets were weighed separately, the average weight was determined, and the weight of each tablet was compared to the average weight to perform the weight variation test.

Table 13: Uniformity of Weight and Percentage Deviation.

S. No.USPMax % Difference AllowedIP / BP
1130mg > or less±10%80mg > or less
2130mg > 324 mg±7.5%80mg-250mg
3324 mg < or>±5%250mg < or>

Content Uniformity Test

A content/potency assay was used in content uniformity testing to ascertain the amount of active substance present in several samples taken during the batch. The UV was used to measure the amount of drug and the consistency of the material. Ten tablets were selected randomly and assay was performed to check individual content of active ingredient in each tablet. The potency of nine out of ten pills must be within 1% to 15% of the drug's stated content. There can only be one tablet within a quarter.

Swelling Index Study

The swelling index of a tablet measures how much its volume increases over a specific amount of time as a result of absorbing a liquid, often a dissolving medium. The swelling state of the polymer is a key factor affecting the tablet's bio adhesion. Until the glue hits a threshold where too much hydration causes the adhesive quality to suddenly drop owing to unwinding at the polymer/tissue interface, the degree of hydration will strengthen the binding.

Mucoadhesive Strength and Time

The force that holds a mucoadhesive substance like a gel or polymer to the mucosal surface like the mucosa of the mouth, nose, or stomach is known as mucoadhesive strength. The mucoadhesive strength was determined by using ex vivo test. Goat intestine was cut to obtain a small piece and pasted on a petri dish using adhesive. The intestine membrane was moistened with 2-3 drops of 0.01 N HCl and the tablet was tied with a thread with physical balance on one side. The total weight required to detach the tablet from the intestine membrane was noted as mucoadhesive strength. 

Disintegration Test of Tablets

The disintegration test shows how quickly and effectively a tablet disintegrates into smaller pieces in a liquid. The disintegration test is performed to confirm that the body is absorbing the medicine as intended. the process for figuring out how long pills take to dissolve. Initially, the disintegration apparatus was filled with distilled water and kept at 37°C± 2°C. The six tablets from each formulation are then chosen at random and put one at a time in each of the six cylinders of a disintegration test device. After that, the device was activated, which caused the basket to move up and down. The time it takes for each pill to completely dissolve is then recorded. The average amount of time it took for the pills to dissolve.

In Vitro Dissolution Test

The medication release profile is ascertained using the in-vitro dissolution test. This is how the mucoadhesive bilayer tablets are tested for in-vitro dissolution. The USP type II paddle-type equipment was used to conduct the in-vitro dissolving test for the bilayer tablets. The paddle's speed was set at 50 rpm, and the water bath's temperature was kept at 37°C +/- 0.5°C. The tank that serves as a dissolving media was filled with 900 milliliters of 0.1 N HCL. A tablet chosen at random is put in the dissolving test apparatus's vessel. The sink state was maintained while a 10-milliliter sample was taken out of the vessel at various prearranged intervals. After the samples were filtered, they were analysed at λmax 290nm using a UV-visible spectrophotometer. The absorbance was recorded, and the percentage of drug release and cumulative drug release was computed.

Stability Studies

Stability studies are a crucial assessment metric that aids in figuring out a product's shelf life or how external factors may impact the final product's quality over time. ICH quick study criteria were used to examine the stability of all salbutamol sulphate tablet formulations for a period of one month. Each sample was securely wrapped in aluminium foil and placed in airtight glass containers. These tablets were exposed to three different temperature settings. Tablets were removed from storage at 10-, 20-, and 30-day intervals for examination, with a focus on physical attributes, drug concentration, and segregation patterns [27-30].

Result and Discussion

Organoleptic properties of Propranolol HCl

Table 14: Organoleptic properties of Propranolol HCl.

S. No.Organoleptic CharacteristicsResult
1ColourWhite
2OdourOdourless
3TasteSlightly bitter
4NatureLipophilic
5CrystallinityCrystalline Solid

Melting Points

While studied done on the Propranolol hcl, the melting point was determined using melting point apparatus was found to be 148.2°C.

Calibration Curve

Table 15: Calibration curve of Propranolol hcl in 0.1 N HCL at λmax 290nm.

S. No.Concentration (µg/ml)Absorbance (λmax 290 nm)
100
220.218
340.339
460.472
580.591
6100.711

Figure 5: Calibration curve of Propranolol HCL in 0.1 N HCL.

Pre-compressional Evaluation

The prepared powder blend for mucoadhesive bilayer tablets were characterized for Angle of repose, Bulk density, tapped density, Carr’s index and Hausner’s ratio for both immediate and mucoadhesive layer which are shown in table. Angle of repose of all batches was within 30°-36°, Carr’s index of all batches was within 7.40-13.20 and Hausner’s ratio of all batches was found within 1.08-1.15 which indicate good flow property of granules.

Table 16: Pre-compressional data of the formulation batches of powder blend.

Formulation batchAngle of Repose(θ)Bulk Density (gm/ cm3)Tapped Density (gm/ cm3)Hausner’s Ratio (HR)Carr’s Index (CI)
MBT 134.560.490.561.1412.5
MBT 233.190.500.541.087.40
MBT 331.620.480.531.109.43
MBT 434.170.490.561.1412.5
MBT 532.870.460.531.1512.5
MBT 633.510.460.531.1513.20
MBT 731.380.510.571.1110.52
MBT 836.430.470.541.1412.9
MBT 936.150.460.531.1513.20
MBT 1030.710.510.571.1110.52
MBT 1134.560.490.541.109.25
MBT 1230.960.470.531.1211.32
MBT 1335.810.500.571.1412.28
MBT 1432.870.460.521.1311.53
MBT 1530.100.510.561.098.92

Post-compressional Evaluation

Shape and Size

On the evaluation of the Propranolol hcl formulated bilayer tablets have the circular in shape and the size of the tablets was found to be 0.65\pm 0.05 cm.

Table 17: Post-compressional data of the formulation batches.

Formulation BatchWeight Variation (mg)Thickness (mm)Hardness (kg/cm2)Swelling Index (ml/g)Mucoadhesive Strength (gm)Disintegration time (sec)Friability (%)
MBT 1451.14.506.218.92914.70.13
MBT 2447.64.515.788.33112.90.17
MBT 3460.44.545.239.12412.70.19
MBT 4445.94.115.217.827170.11
MBT 5454.34.215.109.13312.20.14
MBT 6443.84.246.558.82919.60.19
MBT 7447.74.555.328.624150.12
MBT 8446.34.534.858.93012.90.12
MBT 9461.14.106.118.72617.20.11
MBT 10454.74.415.619.224190.14
MBT 11447.54.485.918.32315.60.15
MBT 12462.94.466.128.52813.70.13
MBT 13447.44.324.559.13513.20.12
MBT 14460.74.274.919.127140.11
MBT 15447.94.275.748.630.512.60.21

All the prepared tablet batches (MBT 1 - MBT 15) were evaluated for post compression parameters and results obtained in the range are sufficient for mucoadhesive bilayer tablets shown in the table no. 17. Hardness ranged between 4.5-6.5kg/cm2, thickness of all tablet batches results from 4.27-4.55mm, friability was found to be in range of 0.11-0.19% which is less than 1% showed good mechanical strength, weight variation test results in between 445.9-462.9mg, swelling index found in 8.3-9.1 ml/gm, mucoadhesive strength results from 14-18.2gm, mucoadhesive time, disintegration time for immediate release layer ranged between 12.2-19.6 seconds. The content uniformity test results ranged between 1.9-2.5% for all the prepared batches.

Stability Studies

The stability studies were done under the accelerated conditions for 1 month and 3 months (40°C ± 5°C / 70% RH ± 5% RH). The propranolol hcl mucoadhesive tablets were evaluated for colour, texture, moisture content, mucoadhesive strength etc., and the results demonstrated that the tablets remained intact physically and there are no visible changes observed. The tablets showed minimal degradation and the in vitro studies suggested that the there is no significant effect on the drug release of both layers. 

In-vitro Dissolution Studies

The amount drug release was analysed at a pre-determined time intervals using a USP type II dissolution test apparatus. The obtained results for cumulative amount of drug release are shown in the Table 18.

Table 18: In vitro dissolution test data of the Propranolol hcl Mucoadhesive bilayer tablets.

Formulation batch5 min10 min20 min30 min40 min60 min120 min180 min240 min480 min720 min
MBT 14.4589.36418.27325.58234.54641.16446.56451.22056.34273.34891.924
MBT 25.4788.34517.99225.18837.98440.37645.49850.04755.05771.57496.756
MBT 34.7958.48717.77424.88635.48843.76149.31854.24958.67476.27689.245
MBT 45.1346.69716.58123.21337.16244.82648.69753.86359.76177.68996.524
MBT 53.4207.98518.06825.29537.70240.58845.65151.21657.75475.80296.752
MBT 65.3248.68118.19325.47236.66441.94447.84152.62557.93276.21595.156
MBT 74.9519.64519.43727.21138.87444.48849.36654.30260.87179.13591.102
MBT 86.3588.12516.34522.95332.68745.90650.92156.01361.89780.46590.561
MBT 95.7539.12617.67926.75637.31443.51248.35753.19259.75477.68489.442
MBT 105.9518.64419.54927.26839.78643.52549.98754.98560.17578.44297.779
MBT 114.1589.14616.99324.79235.90744.28448.68453.54959.12176.78194.304
MBT 126.1478.46418.71526.20137.43142.43549.95255.94261.24880.12194.353
MBT 133.9636.84617.39524.35334.61740.70543.6851.04857.87475.15695.979
MBT 44.8469.86619.37227.12838.54642.25646.31450.94455.35771.65392.104
MBT 154.7827.89116.22722.71737.52445.43550.46254.50859.84977.83792.856

Figure 6: Percent drug release for all the batches MBT 1-MBT 15.

Preparation of Propranolol Hcl Mucoadhesive Bilayer Tablets with Responses

Table 19: The BBD composition of Propranolol hcl Mucoadhesive bilayer tablets formulations and their measured responses.

Formulation BatchIndependent VariablesDependent Variables
Concentration of DisintegrantEffect of Mucoadhesive PolymerEffect of Sustain Release PolymerDisintegration Time (Seconds)Mucoadhesive Strength (Grams)In-Vitro Dissolution Time (%)
MBT 12021.51614.718.291.924
MBT 21621.51812.917.996.756
MBT 316251612.71489.245
MBT 41218181712.796.524
MBT 51621.51812.218.396.752
MBT 612251819.615.195.156
MBT 72021.5201518.291.102
MBT 816181612.911.990.561
MBT 91221.51617.218.689.442
MBT 102025181911.997.792
MBT 111221.52015.616.694.304
MBT 1216252013.714.194.353
MBT 131621.51813.217.495.979
MBT 142018181412.992.104
MBT 1516182012.616.392.856

Response 1: Disintegration Time for Immediate Release Layer

3D and 2D contour plot images show that an increase in the concentration of Disintegrant leads to decrease disintegration time but only at optimum value. Increase in the mucoadhesive polymer also increases the disintegration time for the tablet which is a significant factor but ideally it should not have any kind of interaction. It could be because of any noise. Sustain release polymer doesn’t have any significant effect on the disintegration time.

Figure 7: The 2D contour plot and 3D surface graph shows that how disintegration time for immediate release layer is affected by factors X1 (effect of disintegrant), X2, (effect of mucoadhesive polymer), X3 (effect of sustained release polymer).

ANOVA for Quadratic Model Response 1: Disintegration Time for Immediate Release Layer

The obtained model for ANOVA is significant and lack of fit is non-significant which represent good model alignment. The ANOVA for Disintegration time is shown in the table no. There is only a 3.05% chance that an F-value this large could occur due to noise. In this case B, A² are significant model terms. Values greater than 0.1000 indicate the model terms are not significant.

Table 20: ANOVA for Disintegration time for immediate release layer (Response 1).

SourceSum of SquaresdfMean SquareF-Valuep-Value 
Model72.9398.106.080.0305Significant
A-Effect of Disintegrant5.6115.614.210.0955 
B-Effect of Mucoadhesive polymer9.0319.036.770.0481 
C-Effect of Sustain release polymer0.045010.04500.03370.8615 
AB1.4411.441.080.3464 
AC0.902510.90250.67660.4482 
BC0.422510.42250.31680.5979 
48.97148.9736.710.0018 
3.6313.632.720.1599 
2.2712.271.700.2493 
Residual6.6751.33   
Lack of Fit6.1432.057.780.1161Not Significant
Pure Error0.526720.2633   
Cor Total79.6014    

Response 2: Mucoadhesive Strength

The 3D and 2D Surface plot studies shows how the mucoadhesive polymer, disintegrant and sustain release polymer affect the mucoadhesive strength of tablet. Higher mucoadhesive polymer represent higher strength, while disintegrant has minimum effect. Red and orange colour shows higher mucoadhesive strength.

Figure 8: The 2D contour plot and 3D surface graph shows that how Mucoadhesive strength is affected by factors X1, X2, X3

ANOVA for Quadratic Model Response 2: Mucoadhesive Strength

The model appears significant with F-value 6.56 and there is only 2.60% chance that F value this large occur due to noise. In this case B² is a significant model term. Means increasing the mucoadhesive polymer leads to increase in mucoadhesive strength while the increasing the mucoadhesive polymer leads to increase in disintegration time. Sustain release polymer have negligible effect on mucoadhesive strength.

Table 21: ANOVA for Mucoadhesive strength (Response 2).

SourceSum of SquaresdfMean SquareF-Valuep-Value 
Model84.7499.426.560.0260Significant
A-Effect of Disintegrant0.405010.40500.28230.6180 
B-Effect of Mucoadhesive polymer0.011310.01130.00780.9329 
sC-Effect of Sustain release polymer0.281310.28130.19600.6765 
AB2.8912.892.010.2151 
AC1.000011.00000.69690.4419 
BC7.0217.024.890.0779 
0.380110.38010.26490.6287 
71.35171.3549.730.0009 
0.463110.46310.32280.5945 
Residual7.1751.43   
Lack of Fit6.7732.2611.090.0838Not Significant
Pure Error0.406720.2033   
Cor Total91.9214    

Response 3: In Vitro Drug Release

The sustain release polymer greatly affect the in vitro drug release rate, higher sustained release polymer promote slow release of drug from dosage unit but decreases the in vitro drug release for desired period while the mucoadhesive polymer also affect the drug release but at the optimum. Orange region indicates the balanced level of both sustained release polymer as well as mucoadhesive polymer. Sustained release polymer helps to improve strength and extend the release but can negatively impact disintegration of tablet.

Figure 9: The 2D contour plot and 3D surface graph shows that how In vitro drug release is affected by factors X1, X2, X3.

ANOVA for Quadratic Model Response 3: In Vitro Drug Release

P-values less than 0.0500 indicate model terms are significant. In this case C, AB, AC, C² are significant model terms. There is non-significant lack of fit which represent model is aligned. And is there is only a 0.43% chance that an F-value this large could occur due to noise.

Table 22: ANOVA for in vitro drug release (Response 3).

SourceSum of SquaresdfMean SquareF-valuep-value 
Model108.25912.0314.710.0043Significant
A-Effect of Disintegrant0.791910.79190.96880.3702 
B-Effect of Mucoadhesive polymer2.5212.523.080.1396 
C-Effect of Sustain release polymer16.37116.3720.020.0066 
AB12.40112.4015.170.0115 
AC8.0818.089.880.0256 
BC1.9811.982.420.1805 
1.2511.251.530.2704 
1.0111.011.230.3177 
65.75165.7580.430.0003 
Residual4.0950.8174   
Lack of Fit3.6931.236.140.1433Not Significant
Pure Error0.400420.2002   
Cor Total112.3414    

As we studied the box behnken design we put the responses that we analysed from the evaluation studies as shown in the table no. 19. then the box behnken design optimized the responses and give the optimized batch of formulation and the optimized batch responses and the formulation are shown in table.

Table 23: Formulation of optimized batch from BBD (MBT 16).

S. No.IngredientQuantities (In mg)
Immediate release layer (200mg)
1Propranolol HCl30
2Potato starch12.35
3Lactose152.65
4Magnesium stearate5
Mucoadhesive extended-release layer (250mg)
1Propranolol HCl50
2Chia seed21.03
3HPMC K4 M16.34
4HPMC K1510
5Aloe vera10
6Microcrystalline cellulose137.63
7Talc5

Table 24: Pre compressional data of optimized batch (MBT 16).

S. No.Pre-compressional Evaluation ParameterResults
1Bulk Density0.45
2Tapped Density0.49
3Hausner’s Ratio1.08
4Carss Index8.163
5Angle of Repose32

Table 25: Post compressional data of optimized batch (MBT 16).

S. No.Post-compression Evaluation ParameterResults
1Weight Variation445.9 mg
2Thickness4.32 mm
3Hardness3.357 kg/cm2
4Swelling Index8.4 ml/gm
5Mucoadhesive Strength18.2 gm
6Disintegration Time15.8 seconds
7Friability0.11 %
8% Drug Release95.981 %

Table 26: In vitro drug release for optimized batch (MBT 16).

Formulation batch5 min10 min20 min30 min40 min60 min120 min180 min240 min480 min720 min
MBT 15.4589.30419.27323.67237.58644.19449.96459.22066.34276.34895.981

Figure 10: Percent drug release of batch MBT 16 (optimised batch).

The obtained Percent drug release of batch MBT 16 (optimised batch) has 95.981 % of drug release in12 hrs. (720 minutes), and the optimized batch was evaluated for all the pre and post compressional parameters required for quality control of dosage form and the obtained results was found between satisfied range.

Conclusion

The presented works demonstrate that the tablets containing the propranolol hydrochloride can be desirably prepared as a mucoadhesive bilayer tablets for the management of hypertension. The tablets were evaluated for all the pre and post compressional parameters. The prepared tablets meet all the basic requirements and necessary standards of quality dosage form. Specialised tablets can be further studied for better patient compliance and scale up processes. The study also determines the incorporation of natural ingredients for cost effective and safe studies. The study explores the need of immediate release of drug in the systemic circulation while the supportive maintenance dose for extended period of time for better management of disease. The study aimed to find the optimized batch using the suitable response surface methodology, Box Behnken design. There was selection of three independent factors for their respective responses. The obtained optimised batch MBT 16 showed the desired outcome showed 95.981% of release in 720 minutes. The optimized batch was also evaluated for the various post compressional parameter, Weight variation (445.9 mg), Thickness (4.32 mm), Hardenss (3.357 kg/cm2), Swelling index (8.4 ml/gm), Mucoadhesive strength (18.2 gm), Disintegration time (15.8 seconds), Friability (0.11%).

Declarations

Acknowledgement

I would like to show my sincere gratitude towards IPS Academy College of Pharmacy for providing the necessary requirements and facilities throughout the study. Lastly, I would like to express my appreciation to all my colleagues and peers for their helpful discussions and moral support, which contributed to the success of this work.

Conflict of Interest

The authors declare no conflict of interest.

References